4d Pharma PLC Result of AGM (5164Q)
June 28 2022 - 9:15AM
UK Regulatory
TIDMDDDD
RNS Number : 5164Q
4d Pharma PLC
28 June 2022
4D pharma plc
(the "Company" or "4D pharma")
Result of AGM
At the annual general meeting of 4D pharma plc (AIM: DDDD;
Nasdaq: LBPS), a pharmaceutical company leading the development of
Live Biotherapeutic products, held earlier today, all resolutions
put to shareholders were duly passed.
The full text of each resolution was included in the notice of
the meeting, which was posted to shareholders on 20 May 2022, and
is available on the Company's website www.4dpharmaplc.com .
The results for the resolutions will shortly be available on the
Shareholder Information section of the Company's website,
www.4dpharmaplc.com .
Ahead of the meeting, the following statement was made:
"On 24 June 2022, David Pike and James Clark of Interpath
Advisory were appointed as administrators of the Company. The
administrators have had no oversight of or involvement in the
preparation or convening of this Annual General Meeting nor in any
of the materials circulated to the Company's shareholders in
advance of this Annual General Meeting [which for the avoidance of
doubt shall include, [but not be limited to], the Notice of Annual
General Meeting dated 25 May 2022 ("AGM Notice") or any enclosures
or documents referred to therein.]
Therefore, the administrators make no statement or
representation in respect of any of the matters raised or discussed
in advance of or during this Annual General Meeting. The
administrators make no comment whatsoever in respect of the AGM
Notice including any information on the Company or its equity
securities, any statements of belief or intent by the Directors,
the resolutions proposed (including any recommendations given by
the Directors in relation to them or reasoning for the resolutions)
or which may be passed at this meeting, or any answers given by the
Directors to questions raised by shareholders in connection with
this Annual General Meeting. The Administrators intend to take
legal advice as to whether any resolutions that are passed at the
meeting are, in all circumstances, legally valid. The
administrators make no comment whatsoever on the appropriateness of
the convening of the Annual General Meeting or the manner in which
the Annual General Meeting is conducted. To the extent that the
implementation of any resolutions passed at this Annual General
Meeting requires the exercise of a management power pursuant to
paragraph 64(1) of Schedule B1 of the Insolvency Act 1986, the
administrators have had no opportunity to consider whether such
implementation is appropriate for the purposes of the
administration and therefore provide no consent in this
regard."
For further information please contact:
4D pharma plc
Duncan Peyton, Chief Executive Officer
ir@4dpharmaplc.com + 44 (0)113 895 0130
Singer Capital Markets - Nominated Adviser
and Joint Broker +44 (0) 20 7496 3000
Philip Davies/James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Stern Investor Relations +1-212-362-1200
Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter/Michelle Boxall
neil@ibcomms.agency / michelle@ibcomms.agency
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D pharma has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase II clinical
trial of MRx0518 in combination with BAVENCIO(R) (avelumab) in the
first-line maintenance setting for urothelial carcinoma , a Phase I
study of MRx0518 in a neoadjuvant setting for patients with solid
tumors, a Phase I study of MRx0518 in patients with pancreatic
cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R)
in irritable bowel syndrome (IBS) which has completed a successful
Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients
with Parkinson's disease is expected to commence in 2022.
Additional preclinical-stage programs include candidates for CNS
disease, immune-inflammatory conditions and cancer. The Company has
a research collaboration with MSD (Merck & Co., Inc.,
Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics
for vaccines.
For more information, refer to https://www.4dpharmaplc.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBSGDLIGDDGDI
(END) Dow Jones Newswires
June 28, 2022 10:15 ET (14:15 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024
